<SEC-DOCUMENT>0001123292-25-000148.txt : 20250320
<SEC-HEADER>0001123292-25-000148.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320163225
ACCESSION NUMBER:		0001123292-25-000148
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kalaris Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001754068
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				831971007
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91605
		FILM NUMBER:		25756956

	BUSINESS ADDRESS:	
		STREET 1:		628 MIDDLEFIELD ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301
		BUSINESS PHONE:		650-249-2727

	MAIL ADDRESS:	
		STREET 1:		628 MIDDLEFIELD ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Allovir, Inc.
		DATE OF NAME CHANGE:	20190521

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ViraCyte, Inc.
		DATE OF NAME CHANGE:	20180924

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001123292-22-000101</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000882095</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>2</amendmentNo>
<securitiesClassTitle>Common Stock, $0.0001 per value</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>03/18/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001754068</issuerCik>
<issuerName>Kalaris Therapeutics, Inc.</issuerName>
<issuerCusip>482929106</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>628 Middlefield Road</com:street1>
<com:city>Palo Alto</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94301</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>GILEAD SCIENCES, INC.</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>723273</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>723273</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>723273</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>3.9</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>Percentage based on 18,702,413 shares of Common Stock outstanding immediately following the effective time (the "Effective Time") of the merger, pursuant to the terms of the Agreement and Plan of Merger, dated as of November 7, 2024, by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer ("Merger Sub"), and Kalaris Tx, Inc. (formerly Kalaris Therapeutics, Inc.), a Delaware corporation ("Legacy Kalaris"), of Merger Sub with and into Legacy Kalaris, with Legacy Kalaris continuing as a wholly owned subsidiary of the Issuer, as disclosed in the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 18, 2025. Immediately following the Effective Time, the Issuer changed its name to "Kalaris Therapeutics, Inc." The Common Stock, which was previously listed on The Nasdaq Capital Market and traded under the ticker symbol "ALVR" through the close of business on March 18, 2025, commenced trading on The Nasdaq Global Market under the ticker symbol "KLRS" on March 19, 2025, and is represented by the new CUSIP number above.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Kalaris Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>628 Middlefield Road, Palo Alto, California, 94301</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Gilead Sciences, Inc.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>333 Lakeside Drive &#13;
Foster City, California 94404</principalBusinessOfficeOrResidenceAddress>
<citizenship>Delaware</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>723,273</amountBeneficiallyOwned>
<classPercent>3.9</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>723,273</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>723,273</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>GILEAD SCIENCES, INC.</reportingPersonName>
<signatureDetails>
<signature>/s/ Andrew D. Dickinson</signature>
<title>Andrew D. Dickinson, Executive Vice President and Chief Financial Officer</title>
<date>03/20/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
